How Zircadia Won an NIH SBIR Phase I for In-Ear Sleep Diagnostics | BW&CO

Quick Answer

Zircadia is a Colorado medical device startup developing an in-ear biosensor for at-home sleep diagnostics. The founders came to BW&CO with a promising technology and a lot of questions about which non-dilutive funding programs fit and how to build a competitive application. BW&CO built a multi-agency funding roadmap, wrote and managed the application process, and supported the team through review. The result was an NIH SBIR Phase I award.

At a Glance

• Client: Zircadia (formerly EerDx), Colorado
• Technology: An in-ear biosensor for at-home sleep diagnostics
• Funding secured: NIH SBIR Phase I
• BW&CO services: Funding roadmap, technical due diligence, proposal writing, project management, registrations support, and review guidance

The Problem Zircadia Is Solving

Millions of people who need a sleep study never get one. In-lab polysomnography is expensive, hard to access, and uncomfortable for patients. Most home sleep tests capture only a limited set of signals, which leaves a gap for patients with more complex sleep disorders.

Zircadia is building a comfortable, earbud-style sensor that patients can use at home to capture the kind of rich sleep data that usually requires a lab visit.

The Challenge

Like many deep-tech founders, the Zircadia team had strong technical and business experience but no clear roadmap for federal funding. They needed answers to questions that come up for almost every early-stage medtech company:

• Which agencies and programs actually fit the technology
• Whether SBIR or STTR was the right mechanism
• What kinds of work, including clinical studies and outsourced development, grant funds can cover
• How to present their team and partners in the strongest light for reviewers
• When to submit to give the application the best chance of success

How BW&CO Helped

1. Built a Multi-Agency Funding Roadmap

BW&CO mapped Zircadia's technology against NIH, NSF, and DoD programs and recommended a strategy that matched each type of work to the agency most likely to fund it. NIH SBIR Phase I was identified as the best fit for clinical validation of the device, with additional pathways kept in reserve so the team always had a next step.

2. Answered the Critical Questions Early

In the first conversations, BW&CO walked the founders through the rules that shape a strong application:

• Clinical work is fundable. NIH allows human studies in Phase I, which made it the right home for validating the device.
• SBIR was the right Phase I mechanism. BW&CO explained how SBIR and STTR compare and recommended the path that kept more funding with the company.
• Outsourcing is normal. Contracting specialized design or clinical research partners is a standard, allowable expense when structured correctly.

3. Ran a Technical Due Diligence Review

Before writing began, a BW&CO project consultant with a biomedical research background reviewed the project against the same five criteria NIH reviewers use: significance, innovation, approach, environment, and investigators. The review confirmed a strong fit and showed where the application would be most compelling.

4. Timed the Submission for Strength, Not Speed

Rather than rushing toward the nearest deadline, BW&CO recommended targeting a later cycle so the team could generate more data first. Submitting a thin application early can lead to a resubmission, and the NIH review calendar can push a second attempt back by months. Waiting for a stronger package was the better bet.

5. Strengthened the Team Story

BW&CO advised Zircadia on how reviewers evaluate the people behind a project:

• Explained the Principal Investigator eligibility rules for SBIR
• Advised on selecting the PI best positioned to lead the Phase I work
• Showed how expert advisors and collaborators can build reviewer confidence
• Helped identify and draft letters of support from partners

6. Wrote the Application and Managed the Process

BW&CO did the heavy lifting so the founders could stay focused on building their product. Clients typically spend only a few hours a week on the process. For Zircadia, BW&CO provided:

• A dedicated project consultant and an assigned writer who met with the team weekly
• A structured proposal preparation plan with small weekly tasks and a shared workspace for data collection
• Full drafting of the application, rather than asking the client to produce a first draft
• Program officer outreach to confirm alignment before submission
• Internal quality review plus feedback from an experienced NIH reviewer

7. Guided the Team Through Review

After submission, BW&CO coached the founders on what comes next: interpreting reviewer feedback, engaging with the program officer, and preparing for Just-in-Time document requests. When the federal SBIR program lapsed before reauthorization, BW&CO tracked the situation closely and kept the team informed on funding timelines.

The Result

Zircadia received an NIH SBIR Phase I award to advance its in-ear sleep diagnostic. The funding is non-dilutive, the company retains full ownership of its IP, and the award provides federal validation as Zircadia moves toward later-stage development. BW&CO continues to support Zircadia's broader funding roadmap.

Key Takeaways for Deep-Tech and Medtech Founders

• Match the work to the agency. NIH and NSF fund different kinds of work. Aligning each aim with the right agency makes every application stronger.
• Check your assumptions. Common beliefs about STTR requirements, clinical work, and outsourcing can steer founders away from their best options.
• Timing is a strategy. Submitting a stronger application a cycle later often beats rushing, especially given resubmission timelines.
• Your team story matters. The right PI and the right advisors can make a small team look highly credible to reviewers.

Frequently Asked Questions

Can NIH SBIR Phase I funding be used for clinical studies?

Yes. NIH allows human subjects research in Phase I, including feasibility and validation studies. NSF SBIR does not fund human testing, so many medtech companies use NIH for clinical validation and NSF for core technology development.

Should a startup with a university license apply for SBIR or STTR?

It depends on the agency and phase. For many NIH Phase I applications, SBIR and STTR are reviewed the same way, and SBIR keeps more of the funding with the company. STTR can make sense when the academic partner plays a central research role, often in later phases.

Can a company apply to NIH and NSF for the same technology?

Yes, as long as each application covers distinct, non-overlapping work. A common approach is to send human clinical validation to NIH and fundamental materials or engineering research to NSF.

Who should be the Principal Investigator on an SBIR application?

The PI must be primarily employed by the small business at the time of award and should be the person best placed to lead the proposed work. Publications and relevant industry experience strengthen reviewer confidence, but an advanced degree is not strictly required.

How much time does a founder need to spend on an SBIR application with BW&CO?

BW&CO handles the writing, project management, and administrative work. Founders typically spend a few hours a week on reviews, data, and weekly check-ins.

Ready to Build Your Funding Roadmap?

BW&CO helps deep-tech, biotech, and medtech founders win SBIR, STTR, and other non-dilutive funding across NIH, NSF, DoD, and more. Schedule a funding fit call to find out which programs match your technology.